Results 141 to 150 of about 3,523,765 (264)

Tau Aggregate Imaging and Transcriptomics of Alzheimer's Disease Brain at Different Stages of Disease

open access: yesAdvanced Science, EarlyView.
The protein aggregates and gene expression in the middle temporal gyrus (MTG) and somatosensory cortex (SOM) of the postmortem brains of 13 Alzheimer's disease patients were studied in detail, revealing that small hyperphosphorylated tau aggregates increase with Braak stage driven by microglial inflammation.
Elizabeth A. English   +9 more
wiley   +1 more source

Chemotherapy‐Activated GSK3β‐DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma

open access: yesAdvanced Science, EarlyView.
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li   +11 more
wiley   +1 more source

Nonimmune Hydrops Fetalis and Lysosomal Storage Diseases

open access: yesPediatrics and Neonatology, 2013
Carlo Bellini
doaj   +1 more source

Metabolomic Insights into Lysosomal Storage Diseases: An Untargeted View. [PDF]

open access: yesMetabolites
Di Carlo G   +12 more
europepmc   +1 more source

Quantitative Visualization of Intracellular Nanometabolism Using Peak‐Shifted Dual‐State Emissive FRET Nanoprobes

open access: yesAdvanced Science, EarlyView.
This study reveals the long‐elusive intracellular dissolution mechanism of carrier‐free nanomedicines. By utilizing peak‐shifted dual‐state emissive FRET nanoprobes (PDFNPs) that undergo a distinct ratiometric fluorescence peak shift upon disassembly, we achieve real‐time, quantitative tracking of dissolution kinetics in live cells.
Farsai Taemaitree   +18 more
wiley   +1 more source

Population Pharmacokinetic/Pharmacodynamic Modeling of Therapeutic Enzymes in Lysosomal Storage Diseases. [PDF]

open access: yesClin Pharmacokinet
Barzel I   +5 more
europepmc   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung   +15 more
wiley   +1 more source

A Dual‐Membrane Biomimetic Nanoplatform Enables Triple‐Modal Therapy Against SARS‐CoV‐2 Through Viral Decoy, Inflammation Neutralizing, and Intracellular RNAi

open access: yesAdvanced Science, EarlyView.
[A&T]MLN is a triple‐modal nanoplatform with siRNA‐loaded LN coated with hybrid ACE2/macrophage membrane. It blocks viral entry, neutralizes IL‐6/IL‐1β/TNF‐α, and delivers siRNA to suppress viral replication. In a murine lung injury model, it attenuates inflammation, offering a multi‐pronged strategy against SARS‐CoV‐2 variants and hyperinflammation ...
Hui Li   +19 more
wiley   +1 more source

Human, economic, and social impact of lysosomal storage diseases. [PDF]

open access: yesOrphanet J Rare Dis
Brignani E   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy